Novo Nordisk’s Phase 3 China Obesity Drug Cuts Almost 20% Body Weight
Novo Nordisk’s experimental obesity drug in China achieved average weight loss of nearly 20% in phase 3 data for overweight patients. The strong efficacy raises competitive pressure on Eli Lilly’s Mounjaro franchise ahead of its planned China launch.
1. Phase 3 China Trial Results
Novo Nordisk reported that its China‐specific obesity therapy delivered an average body weight reduction of nearly 20% in overweight and obese patients, marking one of the strongest efficacy outcomes in the market to date.
2. Competitive Implications for Eli Lilly
The robust trial performance is likely to intensify head-to-head competition with Lilly’s Mounjaro, potentially pressuring Lilly’s market share projections and pricing strategies ahead of its own regulatory filings in China.
3. China Market Outlook
China represents the second-largest global market for obesity treatments, and such compelling local data could accelerate regulatory approval timelines and drive rapid adoption by payers and prescribers, reshaping regional market dynamics.